INTRODUCTION {#sec1-1}
============

Azoospermia affects approximately 1% of the male population, accounts for over 15% of all male infertility,[@ref1][@ref2][@ref3] and includes genital tract obstruction (obstructive azoospermia) and spermatogenic impairment (nonobstructive azoospermia, NOA).[@ref4][@ref5] NOA is mainly caused by severely impaired spermatogenesis and is reported to account for more than 70% of azoospermia in Korean patients.[@ref6] Chromosomal abnormalities, such as Klinefelter syndrome, balanced chromosomal rearrangements, and Yq microdeletions, are well known genetic causes of NOA.[@ref7] In many cases, the genetic etiology remains unknown. Matzuk and Lamb[@ref8] reviewed many genes involved in spermatogenesis and mutations in some of those genes were identified in patients with NOA.[@ref9][@ref10][@ref11]

The stromal antigen 3 (*STAG3*) gene was mapped to chromosome 7 and consists of 34 exons encoding a protein involved in the meiotic cohesion complex.[@ref12] Human *STAG3* is highly expressed in the testis and several other organs including the ovary.[@ref13][@ref14] During meiosis, STAG3 forms a cohesion core with three other proteins, structural maintenance of chromosome 3 (SMC3), structural maintenance of chromosomes 1β (SMC1β), and Rad21 cohesin complex component like 1 (Rad21L1).[@ref15][@ref16] In mice, defective Stag3 protein causes aberrant meiotic chromosomal features and infertility.[@ref17][@ref18] In humans, a homozygous 1-bp deletion in *STAG3* has been found in a consanguineous family with premature ovarian failure (POF),[@ref18] and a homozygous donor splice-site mutation has been found in two sisters with premature ovarian insufficiency (POI).[@ref19] Therefore, *STAG3* has been suggested as a strong candidate gene target for causing male infertility.[@ref14][@ref20][@ref21] To date, no homozygous or compound heterozygotic mutations of *STAG3* have been identified in patients with spermatogenic impairment, and studies of *STAG3* mutations have not been examined in infertile male populations.

In this study, we investigated whether *STAG3* variations may be a genetic cause of spermatogenic impairment in Korean men.

PATIENTS AND METHODS {#sec1-2}
====================

 {#sec2-1}

### Subjects {#sec3-1}

A total of 120 Korean men with spermatogenic impairment (43 oligozoospermic and 77 azoospermic) and 245 normal controls were obtained from the Cha Gangnam Medical Center at Cha University, Seoul, Korea, between January 2010 and December 2012. General and clinical characteristics of patients and controls are presented in **[Table 1](#T1){ref-type="table"}**. Patients with tubule obstruction, chromosomal abnormalities, or microdeletion of the Y chromosome AZF region were excluded. Normal controls had a normal sperm concentration and no history of infertility. Testicular size was measured by a Prader orchidometer (Pro-Health Product Ltd., Guangzhou, China). Serum testosterone, follicle-stimulating hormone (FSH), and luteinizing hormone (LH) were measured on a Cobas e601 analyzer (Roche Dignostics, Penzberg, Germany) using electrochemiluminescence immunoassay (ECLIA) method. Semen analysis was performed according to the World Health Organization criteria (WHO, 2010).[@ref22] The study was approved by the Institutional Review Board of Cha Gangnam Medical Center, Seoul, Korea, and written informed consent was obtained from all participants.

###### 

Participants' clinical characteristics

  *Characteristics*                                 *Patients with spermatogenic impairment (43 oligozoospermia + 77 azoospermia)*   *Controls*   *P*
  ------------------------------------------------- -------------------------------------------------------------------------------- ------------ --------
  Patients (n)                                      120                                                                              245          
  Age (year), mean±s.d.                             33.9±3.7                                                                         33.5±2.6     0.783
  Semen volume^a^ (ml), mean±s.d.                   2.9±1.2                                                                          3.3±1.5      0.591
  Sperm concentration^a^ (10^6^), mean±s.d.         10.0±5.4                                                                         74.9±28.0    \<0.01
  Sperm motility^a^ (%), mean±s.d.                  26.8±12.6                                                                        45.7±11.1    0.013
  Sperm morphology^a^ (% normal forms), mean±s.d.   2.0±1.3                                                                          6.4±2.1      \<0.01
  Rt. testis volume (ml), mean±s.d.                 16.0±6.2                                                                         23.0±2.7     0.020
  Lt. testis volume (ml), mean±s.d.                 17.0±6.2                                                                         23.0±2.7     0.025
  Serum FSH (mIU ml^−1^), mean±s.d.                 17.6±10.7                                                                        4.4±1.6      \<0.01
  Serum testosterone (ng ml^−1^), mean±s.d.         4.0±1.1                                                                          3.6±1.5      0.486
  Serum LH (mIU ml^−1^), mean±s.d.                  5.5±2.4                                                                          3.9±2.0      0.106

^a^Data of the azoospermic patients were excluded. s.d.: standard deviation; Rt: right; Lt: left; FSH: follicle-stimulating hormone; LH: luteinizing hormone

### DNA extraction {#sec3-2}

Genomic DNA was isolated from peripheral blood of the patient and control samples with the QuickGene DNA blood kit (KURABO industries, Neyagawa, Japan), according to the manufacturer\'s instructions. DNA yield was quantified with the NanoDrop™ spectrophotometer (Thermo Scientific, Wilmington, DE, USA). The extracted DNA was stored at −80°C until further analysis.

### Polymerase chain reaction {#sec3-3}

Coding regions of *STAG3* (NM_001282716.1) were amplified for genetic screening by polymerase chain reaction (PCR), using primers for the 34 exons and their intron boundaries that were designed by Primer 3 (<http://primer3.ut.ee>). As this gene has multiple pseudogenes, we performed long-range PCR that produced eleven fragments and designed eleven primer pairs to cover the 34 exons and avoid pseudogene sequences. The locations and sequences of primer sets are presented in **[Supplementary Table 1](#T2){ref-type="table"}**.

###### 

The list of polymerase chain reaction primer and sequencing primer sequences

  *n*   *Range*                   *PCR primer Sequence (5' *→* 3')*   *Range*                   *Sequencing primer Sequence (5'*→*3')*       
  ----- ------------------------- ----------------------------------- ------------------------- ---------------------------------------- --- ------------------------
  P1    Exon1 (404bp)             F                                   CGCCCAATGGAGTAGGAGAT      Exon1 (404bp)                            F   CGCCCAATGGAGTAGGAGAT
  R     ACCTGTCAGAGCCTGGAAGA      R                                   ACCTGTCAGAGCCTGGAAGA                                                   
  P2    Exon2-Exon5 (7,413bp)     F                                   TACCACACCCAGTGTGCAAT      Exon2 (294bp)                            F   GCCCTTTCTTCTCTTTCTTCC
  R     GGGGGTACCACAGCTACAGA      R                                   TCCCACGCATATTATCATCAA                                                  
                                  Exon3 (394bp)                       F                         AAAAAGACTTTGTCCCAACTTCC                      
                                  R                                   CGGCTCACTGCAAGCTCT                                                     
                                  Exon4 (538bp)                       F                         GGTTCAGGTGATACGGTTCAT                        
                                  R                                   TGTTCACGTCAAATCAAGTTTGT                                                
                                  Exon5 (450bp)                       F                         TTGTTTACCTCCCAGGGTTG                         
                                  R                                   AGTGCCCGGCCTAAATAAGT                                                   
  P3    Exon6-Exon8 (7,971bp)     F                                   CTTATTGCCATGGCTTCGTT      Exon6 (297bp)                            F   CCCACCTAAGCTCTTTGCAG
  R     CCTGTGGCACATTTTGGTAA      R                                   TTCCTCCTTCTAAAAGCTACCC                                                 
                                  Exon7 (365bp)                       F                         GCCCCTATGACTTCATGGAC                         
                                  R                                   AGCCAAGATGCAGGTAGGAA                                                   
                                  Exon8 (395bp)                       F                         TCATTGCCCTTCTTTCCTTC                         
                                  R                                   ACCCCTTACAGGATGGGTCT                                                   
  P4    Exon9-Exon13 (3,748bp)    F                                   TCCGAATAACCACATGCAGA      Exon9 (330bp)                            F   CGGGGGTTCACACTATCCTA
  R     GCTCAGCACAACAGGAAACA      R                                   ATTTTTGCTCCAGCTGCATT                                                   
                                  Exon10 (433bp)                      F                         CCATGAGAGGGAGTTATCTGG                        
                                  R                                   CTCCCCGTACCTCAGGTTTT                                                   
                                  Exon11 (300bp)                      F                         AATGAGGGATCGGAGAGG                           
                                  R                                   GCTGGGATAGCCAAGACATC                                                   
                                  Exon12 (399bp)                      F                         TCTTGGCTATCCCAGCATCT                         
                                  R                                   CCCCCTCAACATACTGCAAC                                                   
                                  Exon13 (425bp)                      F                         TGCAGTATGTTGAGGGGGTA                         
                                  R                                   GCTGCGAGAAGAAAGGAGAC                                                   
  P5    Exon14-Exon17 (1,893bp)   F                                   ATCTGCTGCTGCCCTACCTA      Exon14 (417bp)                           F   TCTCCCTGGTGTCTCCTTTC
  R     AAGCAGCTGAGAAGCTGGAG      R                                   AGGCTGGTCTCAAACTCCTG                                                   
                                  Exon15 (352bp)                      F                         AATGGAGAAGGATGGGAGTG                         
                                  R                                   CACCTTCCAACTCCAAGCTC                                                   
                                  Exon16 (460bp)                      F                         TGCTGGAGAAGGACCAGAGT                         
                                  R                                   TGCTGGGATTATAGGCGTAA                                                   
                                  Exon17 (400bp)                      F                         AAATCTCGTGGGAGCTACTGA                        
                                  R                                   AAGCAGCTGAGAAGCTGGAG                                                   
  P6    Exon18-Exon21 (1,082bp)   F                                   GGGGGTGGGAGTAGGAATTA      Exon18 (248bp)                           F   GGGGGTGGGAGTAGGAATTA
  R     CTTCCTCGCTTTGTCCACTC      R                                   GGAACCCAAGTTCTTAGGAAAAA                                                
                                  Exon19 (387bp)                      F                         AATGCTTTTAACCCCGTTCC                         
                                  R                                   CAATAGCATTTCCCCCAGAA                                                   
                                  Exon20\~21 (526bp)                  F                         AGCAGGAGCTTGAAGAGCTG                         
                                  R                                   CTTCCTCGCTTTGTCCACTC                                                   
  P7    Exon22-Exon25 (1,237bp)   F                                   GAGTGGACAAAGCGAGGAAG      Exon22\~23 (553bp)                       F   GATGCCTCTGAAGAATGTCCA
  R     TTGGATATCCCCCACCTGTA      R                                   AAAAGCCTGTAGGGGGAAAA                                                   
                                  Exon24\~25 (626bp)                  F                         GGAGCAACAAGGCGAGTATC                         
                                  R                                   TTGGATATCCCCCACCTGTA                                                   
  P8    Exon26-Exon29 (1,565bp)   F                                   TTATTTTGGGCTTTGCACCT      Exon26 (344bp)                           F   GGAGTTTGGGAGGGAGACAT
  R     TACCCACACACAGCACCCTA      R                                   AAGAATGAAGGAACCTATCACG                                                 
                                  Exon27 (371bp)                      F                         CAAGGCCTTTGGAATTTCTG                         
                                  R                                   AAGGCATACCCACCCCTAAC                                                   
                                  Exon28\~29 (602bp)                  F                         GGGTATGCCTTTGGAGACAA                         
                                  R                                   CCCTGAATGACAGTAGATGCTC                                                 
  P9    Exon30-Exon32 (2,057bp)   F                                   AGCCCAGGGGTATGTCTCTT      Exon30 (427bp)                           F   TAGGGCTATGCCCATTTGAG
  R     GGAGGATAGGGGGTCATGTT      R                                   ACAGCAGGGAACCATGAAAC                                                   
                                  Exon31 (387bp)                      F                         CTCCCACATTGTTGGGTTCT                         
                                  R                                   TGACAGGAAGTGCTCTGTGG                                                   
                                  Exon32 (394bp)                      F                         CTCACCCATTGCCTCTCTGT                         
                                  R                                   TCTAGATTCATTCAGCTTTTCCA                                                
  P10   Exon33 (307bp)            F                                   TTTGCGAAGTGACAGGAGTG      Exon33 (307bp)                           F   TTTGCGAAGTGACAGGAGTG
  R     TACACAGGACACAGCAACGG      R                                   TACACAGGACACAGCAACGG                                                   
  P11   Exon34 (490bp)            F                                   GGGCTTTGAGGGTAACCCAGGG    Exon34 (490bp)                           F   GGGCTTTGAGGGTAACCCAGGG
                                  R                                   CGATCTCAAGCCACACCTTGG                                              R   CGATCTCAAGCCACACCTTGG

PCR: polymerase chain reaction

### Sequencing analysis {#sec3-4}

All eleven PCR products were purified with ExoSAP-IT (USB Corporation, Cleveland, OH, USA). To sequence the eleven fragments, we designed 30 sequencing primers to cover 34 exons (**[Supplementary Table 1](#T2){ref-type="table"}**). All the samples were amplified by PCR and sequenced bidirectionally using the BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Austin, TX, USA) and BigDye® X-Terminator™ solutions (Applied Biosystems, Bedford, MA, USA) with standard conditions. The sample supernatant was loaded on the ABI 3130XL Genetic Analyzer (Applied Biosystems, Foster City, CA, USA) and processed with a BigDye® X-Terminator run module. All assays were repeated once for confirmation and the results matched over 99.0%.

### Statistical analyses and database search {#sec3-5}

For each sequence variation, the data were statistically analyzed with Statistical Package for the Social Sciences software (SPSS version 22, IBM Software Group, Chicago, IL, USA). To evaluate the association between patient and control groups, odds ratios (OR), 95% confidence intervals (95% CI), and the applied *P* values were calculated from both the Chi-squared test and Fisher\'s exact test (two-tailed). Applied *P* \< 0.05 were considered statistically significant. Three databases, Polyphen-2, SIFT, and Mutation Tester, were used to predict potentially damaging effects due to amino acid changes.

Multiple hypothesis testing was performed with the Benjamini--Hochberg method[@ref23] to control false discovery rate (FDR) in the logistic regression analysis. Calculating the FDR is a way to address problems associated with multiple comparisons, and FDR provides a measure of the expected proportion of false-positives in the data.

Haplotype block structure was established by HaploView 4.1 software (<https://www.broadinstitute.org>) using the method of block definition of Gabriel *et al.*[@ref24] Haplotype association tests were also conducted with this software.

### Molecular cloning {#sec3-6}

The entire 3'-untranslated region (3'-UTR) of *STAG3* was amplified from genomic DNA, which contained the rs1052482 A or T alleles, using primers that included *Sac*I and *Xba*I restriction sites. Primer sequences of the *STAG3* 3'-UTR were: forward: 5'-GAGCTCccgttgctgtgtcctgtgta, reverse: 5'-TCTAGAgaccaagaacctgacctcca (for a predicted 476 bp product). PCR products were cloned into the pmirGLO vector (Promega, Madison, WI, USA) via the *Sac*I and *Xba*I sites and all constructs were verified by DNA sequencing.

### Dual luciferase assay {#sec3-7}

HEK293T cells were seeded in 48-well plates (3 × 10[@ref4] per well). After 24 h, 200 ng pmir-rs1052482A, pmir-rs1052482T, or pmir-empty vector was transiently transfected with Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). The Renilla vector was used as an internal control for transfection efficiency. After 48 h, the transfected cells were harvested and lysed with a dual-luciferase reporter assay system (Promega), and the activities of Firefly and Renilla were measured in a Luminometer, Centro XS LB960 (Berthold Technologies, Bad Wildbad, Germany), and MikroWin2000 software (<https://mikrowin-20001.software.informer.com>). Transfection experiments were performed in triplicate, and activity measurements were done for three times. Relative luciferase activity was determined by normalizing firefly luciferase activity against Renilla luciferase activity. An average value of firefly/Renilla was calculated and then normalized to the average value of the empty vector to yield the vector-normalized ratio.

### MicroRNAs (miRNAs) {#sec3-8}

Computational prediction of putative targets for *STAG3* mRNA was performed by searching mirmap.ezlab.org, www.targetscan.org, www.microrna.org, and www.mirdb.org for the target prediction algorithms. From the potential miRNAs interacting with *STAG3* mRNA 3'-UTR, we selected seven candidate miRNAs (*miR-148a, miR-2909, miR-3162-5p, miR-33a-5p, miR-33b-5p, miR-4739*, and *miR-6508-3p*) that allowed rs1052482A or T alleles to be included in the seed sequence. Seven miRNAs and their inhibitors were constructed by Bioneer (Daejeon, Korea). The prediction score of the seven miRNAs and the 3'-UTR of *STAG3* and details for their *in silico* interactions are presented in **Supplementary Figure 1** and **[Supplementary Table 2](#T3){ref-type="table"}**. Mimics (5--10 pmol) were transiently cotransfected with pmir-vectors with Lipofectamine 2000 according to the manufacturer\'s instructions.

###### 

miRNA target-site prediction software score

  *Software*    *mirmap.org*   *TargetScan*   *microrna.org*   *mirdb.org*
  ------------- -------------- -------------- ---------------- -------------
  miR-148a      87.6           −0.20          −0.27            
  miR-2909      26.3                                           
  miR-3162-5p   93.0           −0.38                           
  miR-33a-5p    7.8                                            
  miR-33b-5p    8.2                                            
  miR-4739      90.6           −0.40                           55
  miR-6508-3p   46.7           −0.19                           

miRmap: miRmap score; TargetScan: context ++ score; microrna.org: mirSVR score; mirdb.org: Target Score

RESULTS {#sec1-3}
=======

Thirty single-nucleotide variations (SNVs) in *STAG3* were identified in this study. The locations, types, frequencies, and *P* values of the variations are presented in **[Supplementary Table 3](#T4){ref-type="table"}**. The distributions of genotypes of all the SNVs followed the Hardy--Weinberg equilibrium in patients and controls. Seven were exonic, 18 were intronic, one was in the 5'-UTR, and four were in the 3'-UTR of the 30 variations. Three exonic variants were nonsynonymous and the other four variants were synonymous. Three variants were found in a patient but not in controls (c.1269C\>T p. Asp423, +112G\>A, +315C\>T); two variants, c.3669+35C\>G and +198A\>T, showed significant differences in the frequency between patient and control groups (*P* = 0.021, OR: 1.79, 95% CI: 1.098--2.918). Haplotype analysis by HaploView 4.1 showed that nineteen variants were separated into five linkage disequilibrium (LD) blocks (**[Figure 1](#F1){ref-type="fig"}**). As shown in **[Table 2](#T5){ref-type="table"}**, in particular, the frequencies of G-C-A (case: control = 0.504: 0.606, *P* = 0.009), G-G-T (case: control = 0.162: 0.075, *P* \< 0.001), and C-C-A (case: control = 0.075: 0.018, *P* \< 0.001) haplotypes in block 5 were significantly different between patients and controls.

###### 

Genotypes and allele distributions of *STAG3* gene variations

  *n*        *db SNP ID*   *Gene Location*   *SNP function*   *Genotype*       *Case (n=120) (%)*   *Control (n=245) (%)*   *OR*    *95% CI*       *P (Fisher)*   ^*\**^*FDR-p*
  ---------- ------------- ----------------- ---------------- ---------------- -------------------- ----------------------- ------- -------------- -------------- ---------------
  1          rs188290003   c.-125C\>A        5'-UTR           CC               117 (97.5)           239 (97.6)              1.000                                 
  CA         3 (2.5)       6 (2.4)           1.021            0.251--4.156     1.000                1.000                                                         
  AA         0 (0)         0 (0)             --               --               --                   --                                                            
  A allele   3             6                 1.021            0.253--4.119     1.000                1.000                                                         
  2          rs7457787     c.-64-247A\>C     Intron           AA               101 (84.2)           198 (80.8)              1.000                                 
  AC         19 (15.8)     42 (17.1)         0.887            0.490--1.604     0.767                0.767                                                         
  CC         0 (0.0)       5 (2.0)           --               --               0.174                0.432                                                         
  C allele   19            52                0.724            0.418--1.255     0.288                0.432                                                         
  3          rs12666107    c.-64-97G\>C      Intron           GG               16 (13.3)            37 (15.1)               1.000                                 
  GC         62 (51.7)     111 (45.3)        1.292            0.665--2.508     0.511                1.000                                                         
  CC         42 (35.0)     97 (39.6)         1.001            0.503--1.995     1.000                1.000                                                         
  C allele   146           305               0.942            0.686--1.294     0.746                1.000                                                         
  4          rs11531577    c.48G\>T          p.Leu16Phe       GG               105 (87.5)           218 (89.0)              1.000                                 
  GT         15 (12.5)     26 (10.6)         1.198            0.609--2.357     0.725                0.867                                                         
  TT         0 (0.0)       1 (0.4)           --               --               --                                                                                 
  T allele   15            28                1.1              0.576--2.101     0.867                0.867                                                         
  5          rs2272343     c.106A\>C         p.Thr36Pro       AA               105 (87.5)           218 (89.0)              1.000                                 
  AC         15 (12.5)     26 (10.6)         1.1978           0.609--2.357     0.725                0.867                                                         
  CC         0 (0.0)       1 (0.4)           --               --               --                                                                                 
  C allele   15            28                1.1              0.576--2.101     0.867                0.867                                                         
  6          rs6465764     c.219+71G\>A      Intron           GG               16 (13.3)            37 (15.1)               1.000                                 
  GA         62 (51.7)     111 (45.3)        1.2917           0.665--2.508     0.511                1.000                                                         
  AA         42 (35.0)     97 (39.6)         1.0013           0.503--1.995     1.000                1.000                                                         
  A allele   146           305               0.9421           0.686--1.294     0.746                1.000                                                         
  7          rs761620488   c.198A\>C         p.Lys66Asn       AA               120 (100.0)          244 (99.6)              1.000                                 
  AC         0 (0.0)       1 (0.4)           --               --               --                                                                                 
  CC         0 (0.0)       0 (0)             --               --               --                                                                                 
  C allele   0             1                 --               --               1.000                1.000                                                         
  8          rs4729579     c.220-64C\>G      Intron           CC               16 (13.3)            37 (15.1)               1.000                                 
  CG         62 (51.7)     111 (45.3)        1.292            0.665--2.508     0.511                1.000                                                         
  GG         42 (35.0)     97 (39.6)         1.001            0.503--1.995     1.000                1.000                                                         
  G allele   146           305               0.942            0.686--11.294    0.746                1.000                                                         
  9          rs2056726     c.220-63G\>A      Intron           GG               105 (87.5)           218 (89.0)              1.000                                 
  GA         15 (12.5)     26 (10.6)         1.198            0.609--2.357     0.725                0.867                                                         
  AA         0 (0.0)       1 (0.4)           --               --               --                                                                                 
  A allele   15            28                1.100            0.576--2.101     0.867                0.867                                                         
  10         rs6960458     c.337-109G\>T     Intron           GG               16 (13.3)            37 (15.1)               1.000                                 
  GT         62 (51.7)     111 (45.3)        1.2917           0.6651--2.5084   0.511                1.000                                                         
  TT         42 (35)       97 (39.6)         1.001            0.503--1.995     1.000                1.000                                                         
  T allele   146           305               0.942            0.686--1.294     0.746                1.000                                                         
  11         rs2272344     c.715+180C\>T     Intron           CC               16 (13.3)            37 (15.1)               1.000                                 
  CT         62 (51.7)     111 (45.3)        1.292            0.665--2.508     0.511                1.000                                                         
  TT         42 (35.0)     97 (39.6)         1.001            0.503--1.995     1.000                1.000                                                         
  T allele   146           305               0.942            0.686--1.294     0.746                1.000                                                         
  12         rs11764176    c.716-104G\>T     Intron           GG               16 (13.3)            37 (15.1)               1.000                                 
  GT         62 (51.7)     111 (45.3)        1.292            0.665--2.508     0.511                1.000                                                         
  TT         42 (35.0)     97 (39.6)         1.001            0.503--1.995     1.000                1.000                                                         
                                                                                                                                                                  
                                                              T allele         146                  305                     0.942   0.686--1.294   0.746          1.000
  13         rs200131656   c.1035A\>G        p.Leu345         AA               111 (92.5)           225 (91.8)              1.000                                 
  AG         9 (7.5)       20 (8.2)          0.912            0.402--2.069     1.000                1.000                                                         
  GG         0 (0)         0 (0)             --               --               --                                                                                 
  G allele   9             20                0.916            0.410--2.042     1.000                1.000                                                         
  14         rs62482167    c.1066-186C\>G    Intron           CC               105 (87.5)           215 (87.8)              1.000                                 
  CG         15 (12.5)     30 (12.2)         1.024            0.528--1.985     1.000                1.000                                                         
  GG         0 (0)         0 (0)             --               --               --                                                                                 
  G allele   15            30                1.022            0.539--1.939     1.000                1.000                                                         
  15         rs3823642     c.1245-26T\>C     Intron           TT               17 (14.2)            39 (15.9)               1.000                                 
  TC         50 (41.7)     96 (39.2)         1.195            0.615--2.322     0.621                0.934                                                         
  CC         53 (44.2)     110 (44.9)        1.105            0.573--2.133     0.868                0.934                                                         
  C allele   156           316               1.023            0.740--1.413     0.934                0.934                                                         
  16         rs755877186   c.1269C\>T        p\. Asp423       CC               119 (99.2)           245 (100.0)             1.000                                 
  CT         1 (0.8)       0 (0.0)           --               --               --                                                                                 
  TT         0 (0)         0 (0)             --               --               --                                                                                 
  T allele   1             0                 --               --               0.329                0.329                                                         
  17         rs3735241     c.1293A\>C        p.Pro431         AA               17 (14.2)            38 (15.5)               1.000                                 
  AC         50 (41.7)     96 (39.2)         1.195            0.615--2.322     0.621                0.934                                                         
  CC         53 (44.2)     111 (45.3)        1.105            0.573--2.133     0.868                0.934                                                         
  C allele   156           318               1.023            0.740--1.413     0.934                0.934                                                         
  18         rs2272345     c.1573+41C\>G     Intron           CC               18 (15.0)            41 (16.7)               1.000                                 
  CG         59 (49.2)     107 (43.7)        1.256            0.663--2.379     0.526                1.000                                                         
  GG         43 (35.8)     97 (39.6)         1.010            0.522--1.954     1.000                1.000                                                         
  G allele   145           301               0.958            0.699--1.315     0.809                1.000                                                         
  19         rs13230744    c.1678-67A\>G     Intron           AA               12 (10.0)            35 (14.3)               1.000                                 
  AG         58 (48.3)     96 (39.2)         1.762            0.847--3.665     0.162                0.485                                                         
  GG         50 (41.7)     114 (46.5)        1.279            0.613--2.668     0.588                0.882                                                         
  G allele   158           324               0.987            0.713--1.367     1.000                1.000                                                         
  20         rs117672080   c.1678-58A\>G     Intron           AA               107 (89.2)           221 (90.2)              1.000                                 
  AG         13 (10.8)     23 (9.4)          1.167            0.569--2.394     0.710                0.860                                                         
  GG         0 (0)         1 (0.4)           --               --               --                                                                                 
  G allele   13            25                1.065            0.535--2.121     0.860                0.860                                                         
  21         rs200967267   c.2133-36C\>A     Intron           CC               117 (97.5)           242 (98.8)              1.000                                 
  CA         3 (2.5)       3 (1.2)           2.068            0.411--10.405    0.399                0.401                                                         
  AA         0 (0)         0 (0)             --               --               --                                                                                 
  A allele   3             3                 2.055            0.412--10.258    0.401                0.401                                                         
  22         rs1043915     c.2445T\>A        p\. Ile815       TT               14 (11.7)            39 (15.9)               1.000                                 
  TA         63 (52.5)     109 (44.5)        1.61             0.812--3.194     0.189                0.556                                                         
  AA         43 (35.8)     97 (39.6)         1.235            0.608--2.508     0.600                0.900                                                         
  A allele   149           303               1.011            0.735--1.389     1.000                1.000                                                         
  23         rs150085849   c.2395-20C\>T     Intron           CC               118 (98.3)           241 (98.4)              1.000                                 
  CT         2 (1.7)       4 (1.6)           1.021            0.184--5.655     1.000                1.000                                                         
  TT         0 (0)         0 (0)             --               --               --                                                                                 
  T allele   2             4                 1.021            0.186--5.614     1.000                1.000                                                         
  24         rs79986079    c.2803-206C\>T    Intron           CC               106 (88.3)           216 (88.2)              1.000                                 
  CT         14 (11.7)     28 (11.4)         1.019            0.515--2.016     1.000                1.000                                                         
  TT         0 (0.0)       1 (0.4)           --               --               --                                                                                 
  T allele   14            30                0.95             0.494--1.827     1.000                1.000                                                         
  25         rs2246713     c.3081-38G\>C     Intron           GG               52 (43.3)            114 (46.5)              1.000                                 
  GC         55 (45.8)     106 (43.3)        1.138            0.717--1.806     0.638                0.847                                                         
  CC         13 (10.8)     25 (10.2)         1.140            0.541--2.404     0.847                0.847                                                         
  C allele   81            156               1.091            0.786--1.514     0.614                0.847                                                         
  26         rs1727130     c.3669+35C\>G     Intron           CC               36 (30.0)            101 (41.2)              1.000                                 
  CG         67 (55.8)     105 (42.9)        1.79             1.098--2.918     0.021                0.063                                                         
  GG         17 (14.2)     39 (15.9)         1.223            0.617--2.426     0.596                0.596                                                         
                                                                                                                                                                  
                                                              G allele         101                  183                     1.219   0.890--1.670   0.226          0.339
  27         rs188384958   +112G\>A          3'-UTR           GG               119 (99.2)           245 (100.0)             1.000                                 
  GA         1 (0.8)       0 (0.0)           --               --               0.329                0.329                                                         
  AA         0 (0)         0 (0)             --               --               --                                                                                 
  A allele   1             0                 --               --               0.329                0.329                                                         
  28         rs1052482     +198A\>T          3'-UTR           AA               36 (30.0)            101 (41.2)              1.000                                 
  AT         67 (55.8)     105 (42.9)        1.79             1.098--2.918     0.021                0.063                                                         
  TT         17 (14.2)     39 (15.9)         1.223            0.617--2.426     0.596                0.596                                                         
  T allele   101           183               1.219            0.890--1.670     0.226                0.339                                                         
  29         rs1727131     +315C\>T          3'-UTR           CC               119 (99.2)           245 (100.0)             1.000                                 
  CT         1 (0.8)       0 (0.0)           --               --               0.329                0.329                                                         
  TT         0 (0)         0 (0)             --               --               --                                                                                 
  T allele   1             0                 --               --               0.329                0.329                                                         
  30         rs12056000    +370G\>A          3'-UTR           GG               105 (87.5)           216 (88.2)              1.000                                 
  GA         13 (10.8)     18 (7.3)          1.486            0.701--3.147     0.322                0.483                                                         
  AA         2 (1.7)       11 (4.5)          0.374            0.081--1.718     0.238                0.483                                                         
  A allele   17            40                0.858            0.476--1.547     0.662                0.662                                                         

STAG3: stromal antigen 3; SNPs: single-nucleotide polymorphism; NOA: nonobstructive azoospermia; OR: odds ratio; CI: confidence interval; FDR-P: false discovery rate-adjusted P value; --: 0, NaN (not a number) or infinity

![LD pattern in the locus of *STAG3* gene. Nineteen variants were separated into five LD blocks. Numbers in the squares indicate D' index (level of LD) between the corresponding SNPs. *STAG3*: stromal antigen 3; SNPs: single-nucleotide polymorphism; LD: linkage disequilibrium.](AJA-22-106-g001){#F1}

###### 

Haplotype analysis between the *SNPs* of *STAG3* and nonobstructive azoospermia

  ----------------------------------------------------------------------------------------------------------
  *db SNP ID*                        *Haplotype*   *Frequency*   *OR (95% CI)*   *P (Fisher)*   *FDR-P*   
  ---------------------------------- ------------- ------------- --------------- -------------- --------- --
  rs12666107 rs11531577 rs2272343\   Block 1                                                              
   rs6465764 rs4729579 rs2056726\                                                                         
   rs6960458 rs2272344 rs11764176                                                                         

   CGAAGGTTT                         0.608         0.622         0.136           0.712          0.812     

   GGAGCGGCG                         0.329         0.320         0.056           0.812          0.812     

   GTCGCAGCG                         0.062         0.057         0.083           0.773          0.812     

  rs62482167 rs3823642 rs3735241     Block 2                                                              

   CCC                               0.650         0.645         0.018           0.892          0.949     

   CTA                               0.287         0.290         0.004           0.949          0.949     

   GTA                               0.062         0.061         0.005           0.946          0.949     

  rs2272345\                         Block 3                                                              
  rs13230744                                                                                              

   GG                                0.595         0.604         0.047           0.829          0.900     

   CA                                0.333         0.328         0.016           0.900          0.900     

   CG                                0.063         0.058         0.086           0.769          0.900     

   GA                                0.009         0.011         0.050           0.823          0.900     

  rs1043915\                         Block 4                                                              
  rs79986079                                                                                              

   AC                                0.621         0.618         0.004           0.949          0.991     

   TC                                0.321         0.320         0.000           0.991          0.991     

   TT                                0.058         0.061         0.264           0.878          0.991     

  rs2246713\                         Block 5                                                              
  rs1727130\                                                                                              
  rs1052482                                                                                               

   GCA                               0.504         0.606         6.817           0.009          0.012     

   CGT                               0.259         0.300         1.356           0.244          0.244     

   GGT                               0.162         0.075         13.028          0.0003         0.001     

   CCA                               0.075         0.018         14.460          0.0001         0.0004    
  ----------------------------------------------------------------------------------------------------------

STAG3: stromal antigen 3; SNPs: single-nucleotide polymorphism; NOA: nonobstructive azoospermia; OR: odds ratio; CI: confidence interval; FDR-P: false discovery rate-adjusted P value

**[Table 3](#T6){ref-type="table"}** shows a genetic model of the 3 SNVs (rs2246713, rs1727130, and rs1052482) between the cases and the controls. We found that the individuals with the CG genotype of rs1727130 and AT genotype of rs1052482 had an increased risk susceptibility to NOA in the codominant model, and those with the minor allele G of rs1727130 and T of rs1052482 had an increased risk susceptibility to NOA in the dominant model (*P* = 0.039, OR: 1.64, 95% CI: 1.030--2.608).

###### 

The genotype distributions of *STAG3* rs2246713, rs1727130, and rs1052482 in the cases and the controls

  *SNPs*      *Model*      *Genotype*   *Case, n (%)*   *Control, n (%)*   *P (Fisher)*   *OR*           *95% CI*   *FDR-P*
  ----------- ------------ ------------ --------------- ------------------ -------------- -------------- ---------- ---------
  rs2246713   Codominant   GG           52 (43.3)       114 (46.5)                                                  
  GC          55 (45.9)    106 (43.3)   0.638           1.138              0.717--1.806   0.638                     
  CC          13 (10.8)    25 (10.2)    0.847           1.140              0.541--2.404   0.847                     
  Dominant    GG           52 (43.3)    114 (46.5)                                                                  
  GC + CC     68 (56.7)    131 (53.5)   0.578           0.879              0.566--1.364   0.578                     
  Recessive   CC           13 (10.8)    25 (10.2)                                                                   
  GC + GG     107 (89.2)   220 (89.8)   0.857           1.069              0.526--2.172   0.857                     
  rs1727130   Codominant   CC           36 (30.0)       101 (41.2)                                                  
  CG          67 (55.8)    105 (42.9)   0.021           1.790              1.098--2.918   0.032                     
  GG          17 (14.2)    39 (15.9)    0.596           1.223              0.617--2.426   0.847                     
  Dominant    CC           36 (30.0)    101 (41.2)                                                                  
  CG + GG     84 (70.0)    144 (58.8)   0.039           1.637              1.030--2.608   0.059                     
  Recessive   GG           17 (14.2)    39 (15.9)                                                                   
  CG + CC     103 (85.8)   206 (84.1)   0.758           0.872              0.471--1.615   0.857                     
  rs1052482   Codominant   AA           36 (30.0)       101 (41.2)                                                  
  AT          67 (55.8)    105 (42.9)   0.021           1.79               1.098--2.918   0.032                     
  TT          17 (14.2)    39 (15.9)    0.596           1.223              0.617--2.426   0.847                     
  Dominant    AA           36 (30.0)    101 (41.2)                                                                  
  AT + TT     84 (70.0)    144 (58.8)   0.039           1.637              1.030--2.608   0.059                     
  Recessive   TT           17 (14.2)    39 (15.9)                                                                   
              AT + AA      103 (85.8)   206 (84.1)      0.758              0.872          0.471--1.615   0.857      

STAG3: stromal antigen 3; SNPs: single-nucleotide polymorphism; OR: odds ratio; CI: confidence interval; FDR-P: false discovery rate-adjusted P value

To determine whether variations in the 3'-UTR region affected miRNA-mediated gene expression regulation, miRNAs predicted to interact with *STAG3* were examined by *in silico* analysis, and seven *miRNAs, miR-148a, miR-2909, miR-3162-5p, miR-33a-5p, miR-33b-5p, miR-4739*, and *miR-6508-3p*, were found potentially to interact with the 3'-UTR of *STAG3* mRNA. The effect of these seven miRNAs on +198A\>T variation (rs1052482) was examined by a luciferase assay. There was no significant difference in relative luciferase activities between rs1052482A and rs1052482T (**[Figure 2a](#F2){ref-type="fig"}**), but a substantial decrease in luciferase activity was observed in cells cotransfected with pmir-rs1052482A and *miR-3162-5p* (mean ± standard deviation \[s.d.\]: 51.6% ± 2.5%, *P* = 0.002), compared with control vector pmir-GLO or pmir-rs1052482T (mean ± s.d.: 85.9% ± 3.6%, *P* = 0.061) (**[Figure 2b](#F2){ref-type="fig"}**). A sequential decrease was observed in cells cotransfected with pmir-rs1052482A and *miR-3162-5p* in proportion to the amount of the mimic (rs1052482A \[mean ± s.d.\], 63.7% ± 1.7%: 45.0% ± 2.7%; rs1052482T \[mean ± s.d.\], 89.2 ± 5.0%: 78.3% ± 1.4%, respectively), and this reduction was inhibited when the *mir-3162-5p* inhibitor was cotransfected with pmir-rs1052482A and *miR-3162-5p* (**[Figure 2c](#F2){ref-type="fig"}**). The data indicate that *miR-3162-5p* targets the rs1052482A sequence more efficiently than that of rs1052482T.

![Relative luciferase activities of pmir-rs1052482A and pmir-rs1052482T in HEK293T cells. **a--c** represent the mean RLU values ± s.d. of triplicates. (**a**) No significant differences in relative luciferase activity among three vectors. (**b**) Luciferase activity was substantially decreased in cells cotransfected with pmir-rs1052482A and *miR-3162-5p* compared to the cells cotransfected with pmir-control and *miR-3162-5p* (*P* \< 0.01). (**c**) A sequential decrease was observed in cells cotransfected with pmir-rs1052482A and *miR-3162-5p* in proportion to the amount of the mimic and this reduction was rescued when the *mir-3162-5p* inhibitor was cotransfected with pmir-rs1052482A and *miR-3162-5p.* -: absence of the indicated one; +: presence of the indicated one; ^\*^*P* \< 0.05 (pmir-rs1052482A + mir3162-5p \[5 pmol\] compared to pmir-rs1052482A); ^\*\*^*P* \< 0.01 (pmir-rs1052482A + mir3162-5p \[10 pmol\] compared to pmir-rs1052482A). CTL: control; RLU: relative light unit; s.d.: standard deviation.](AJA-22-106-g002){#F2}

DISCUSSION {#sec1-4}
==========

Many autosomal genes such as ring finger protein 212(*Rnf212*), testis expressed 15(*Tex15*), syntaxin 2(*Stx2*), and siah E3 ubiquitin protein ligase 1A(*Siah1a*)are reported to be crucial factors for the meiotic process and spermatogenesis in mouse studies.[@ref25][@ref26][@ref27][@ref28] Human homologs of these genes also play a role in meiosis, and variations of these genes are thought to induce spermatogenic impairment.[@ref8][@ref29][@ref30][@ref31] In recent studies, the homologous deletion of *Stag*3 has been shown to induce sterility associated with the premature arrest of meiotic prophase I in both male and female mice.[@ref18][@ref32] Therefore, we have investigated the association between *STAG3* gene variations and male infertility.

We identified 30 variations in the coding regions and intron boundariesof *STAG3* in patients with NOA and in control samples. Of the 30 variations, seven were exonic and three were found only in different infertile patients. For these variations, we evaluated the potential pathogenic effects by three prediction methods, Polyphen-2, SIFT, and Mutation Taster (**[Table 4](#T7){ref-type="table"}**). Most variations (six of nine) were considered benign and three variations did not show consistent results in the three predictive programs. Minor allele frequencies (MAFs) of these variations were not significantly different between patients and controls, and these MAFs were similar to those of other Asian populations on the NCBI SNP database from the 1000 Genomes Project. Considering these data, the above-mentioned variations are unlikely to be related to the spermatogenic impairment in our Korean male population. Interestingly, two variations, c.3669+35C\>G and +198A\>T (rs1727130 and rs1052482) located in 3'-UTR, had a significantly different frequency between the patient and control groups. However, there is a discrepancy in this result. According to Yu *et al.*,[@ref33] there is no significant difference in the frequencies of allele and genotype at SNP rs1052482 between patients with NOA and controls and they suggested that this SNP is not associated with azoospermia. Two variants of rs1727130 and rs1052482 are close together (372 bp apart) and tightly linked, as shown in the LD block analysis. The allele distribution of 2 SNVs between the patient and control groups is more evident in the LD block analysis. On the basis of the data, we propose that multiple SNVs linked to a block can interact with each other to regulate gene function, rather than allowing each SNV to function independently.

###### 

*In silico* analysis for exonic variations and three variations found only in patients

  *n*   *db SNP ID*   *Gene location*   *AA change*   *In silico variant analysis*                   
  ----- ------------- ----------------- ------------- ------------------------------ --------------- -----------------
  1     rs11531577    c.48G\>T          p.Leu16Phe    Benign (1.00/0.00)             Not tolerated   Polymorphism
  2     rs2272343     c.106A\>C         p.Thr36Pro    Benign (1.00/0.00)             Not tolerated   Polymorphism
  3     rs761620488   c.198A\>C         p.Lys66Asn    Benign (0.98/0.44)             Tolerated       Polymorphism
  4     rs200131656   c.1035A\>G        p.Leu345      --                             Tolerated       Disease causing
  5     rs755877186   c.1269C\>T        p.Asp423      --                             Tolerated       Polymorphism
  6     rs3735241     c.1293A\>C        p.Pro431      --                             Tolerated       Polymorphism
  7     rs1043915     c.2445T\>A        p.Ile815      --                             Tolerated       Polymorphism
  8     rs188384958   +112G\>A          3'-UTR        --                             --              Polymorphism
  9     rs1727131     +315C\>T          3'-UTR        --                             --              Polymorphism

^a^http://genetics.bwh.harvard.edu/pph 2/; ^b^SIFT, http://siftdna.org/; ^c^www.mutationtaster.org. AA: amino acid; --: no result; SIFT: sorting intolerant from tolerant

The presence of SNVs in the 3'-UTR of genes may interfere with mRNA stability and translation through effects on polyadenylation and regulatory protein--mRNA and miRNA--mRNA interactions, or may locally alter secondary structures of mRNAs, affecting the accessibility of binding sites for interacting transelements.[@ref34][@ref35][@ref36]

We investigated whether rs1052482, the SNV in the 3'-UTRof *STAG3*, could affect interaction with miRNAs and thus affect posttranscriptional repression of *STAG3*. When pmir-rs1052482A was cotransfected with *miR-3162-5p*, a substantial decrease was observed in luciferase activity compared with pmir-rs1052482T. This result suggests that rs1052482 is located within a binding site for *miR-3162-5p* in the *STAG3* 3'-UTR, and the minor rs1052482T allele may offset the inhibition by *miR-3162-5p*.

According to Fukuda *et al.*,[@ref17][@ref37] STAG3 interacts with the three different α-kleisin subunits present in mammalian meiotic cells, depending on the temporal and spatial distribution. STAG3 combined with meiotic recombination protein (REC8), one of the α-kleisin subunits, and promoted synapsis between homologous chromosomes, while the same complexes inhibited synaptonemal complex assembly between sister chromatids. Therefore, we hypothesize that *STAG3* with the rs1052482T variation reduces the normal inhibitory function of *mir-3162-5p*, thereby increasing the amount of STAG3 protein and ultimately disturbing synapses between homologous chromosomes or sister chromatids. However, it is unclear how elevated STAG3 may affect meiotic chromosome dynamics. In previous studies, *mir-3162-5p* was identified as a regulator of prostate or cervical antigen in cell carcinomas.[@ref38][@ref39][@ref40] However, little is known about *mir-3162-5p*\'s regulation of human meiosis, because of the difficulties in uncovering the spatiotemporal and sequential expression of miRNAs in human germ cells, and identifying which miRNAs are the actual operators for the onset of meiosis or spermatogenesis.

CONCLUSION {#sec1-5}
==========

We have identified 30 SNVs of *STAG3* in the Korean population. Pathogenic variations that directly cause NOA were not identified. However, we found that two SNVs, rs1727130 and rs1052482, located in the 3'-UTR region may be associated with the NOA phenotype through the regulation of miRNA. Further studies are needed to determine whether variations in the 3'-UTR region of *STAG3* actually affect gene expression through miRNAs, including *mir-3162-5p* in germ cells. While there is still much to learn about the exact mechanisms regulating human meiosis or spermatogenesis, our findings contribute to the understanding of spermatogenic impairment, as well as the identification of predictive susceptibility biomarkers.
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Schematic diagram of luciferase reporter construct and *in silico* interaction of the potential microRNAs with rs1052482 of STAG3 Seven candidate miRNAs (miR-148a, miR-2909, miR-3162-5p, miR-33a-5p, miR-33b-5p, miR-4739, and miR-6508-3p) that allow rs1052482A or T alleles to be included in the seed sequence. STAG3: stromal antigen 3.
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